A Study of RAY1225 in Participants With Obesity

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Obesity

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06254261

Enrollment

270

Registered

2024-02-12

Start date

2024-02-21

Completion date

2025-12-20

Last updated

2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

Interventions

DRUGRAY1225

Administered SC

DRUGPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Have a body mass index (BMI) of ≥28 kilogram per square meter (kg/m²) or ≥24 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, fatty liver disease,or HbA1c ≥5.7% and \< 6.5%; 2. Participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.

Exclusion criteria

1. Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity 2. with a history of diabetes or hypoglycemia; 3. Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator. 4. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening) 5. allergic constitution; 6. not suitable for subcutaneous injection.

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline in Body Weight	Baseline,Week26	Percent Change from Baseline in Body Weight

Secondary

Measure	Time frame
Percentage of Participants Who Achieve ≥10% Body Weight Reduction	Baseline,Week26
Percentage of Participants Who Achieve ≥15% Body Weight Reduction	Baseline,Week26
Percentage of Participants Who Achieve ≥5% Body Weight Reduction	Baseline,Week26
Change from Baseline in Waist Circumference in Centimeter	Baseline,Week26

Countries

China

Contacts

Primary ContactJI, professor

iao@pkuph.edu.cn88326666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026